Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia

References

• Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology group (ECOG) 2993 trial. Blood. 2007;109:3189–3197.
   PubMed Web of Science ®Google Scholar
• Motlló C, Ribera JM, Morgades M, et al. Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Cancer. 2014;120:3958–3964.
   PubMed Web of Science ®Google Scholar
• Motlló C, Ribera JM, Morgades M, et al. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Leuk Lymphoma. 2017;58:145–152.
   PubMed Web of Science ®Google Scholar
• Parma M, Viganò C, Fumagalli M, et al. Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission. Mediterr J Hematol Infect Dis. 2015;7:e2015041.
   PubMed Web of Science ®Google Scholar
• Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0469 protocol. Blood. 2005;105:3434–3441.
   PubMed Web of Science ®Google Scholar
• Pullarkat V, Slovak ML, Kopecky KJ, et al. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008;111:2563–2572.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Ortega JJ, Oriol A, et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica. 2002;87:154–166.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125:3711–3719.
   PubMed Web of Science ®Google Scholar
• Fieding AK. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: a broader range of options, improved outcomes, and more therapeutic dilemmas. Am Soc Clin Oncol Educ Book. 2015;35:e352–e359.
   Google Scholar
• Daver N, Thomas D, Ravandi F, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100:653–661.
   PubMed Web of Science ®Google Scholar
• Ribera JM. Optimal approach to the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools. Leuk Lymphoma. 2013;54:21–27.
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121:4158–4164.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547–1555.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Coudé MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128:774–782.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Dombret H, Chevallier P, et al. Complete molecular and hematologic response in adult patients with relapse/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with Blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTARA). Blood. 2015;126:679.
   Web of Science ®Google Scholar
• Park JH, Riviere S, Wang X, et al. Implications of minimal residual disease negative complete remission (MRD-CR) and allogenenic stem cell transplant on safety and clinical outcome of CD-19-targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL. Blood. 2015;126:682.
   Web of Science ®Google Scholar
• Aldoss I, Stiller T, Cao TM, et al. Impact of additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21:1326–1329.
   PubMed Web of Science ®Google Scholar
• Shaffer LG, Slovak ML and Campbell LJ, editors. ISCN 2013: an international system for human cytogenetic nomenclatures. Basel: Karger; 2013.
   Google Scholar
• Ribera JM, García O, Montesinos P, et al. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. Br J Haematol. 2012;159:78–81.
   PubMed Web of Science ®Google Scholar
• Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26:4791–4797.
   PubMed Web of Science ®Google Scholar
• Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Norhtern Italy Leukemia Group protocol 09/00. JCO. 2010;28:3544–3552.
   Web of Science ®Google Scholar
• Kebriaei P, Saliba R, Rondon G, et al. Long-term follow-up of allogenenic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012;18:584–592.
   PubMed Web of Science ®Google Scholar
• Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant. 2013;19:150–155.
   PubMed Web of Science ®Google Scholar
• Short NJ, Kantarjian HM, Sasaki K, et al. Poor outcomes associated with + der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017;92:238–243.
   PubMed Web of Science ®Google Scholar
• McQuilten ZK, Sundararajan V, Adrianopoulos N, et al. Monosomal Karyotype predicts inferior survival independently of a complex karyotype in patients with myelodysplastic syndromes. Cancer. 2015;121:2892–2899.
   PubMed Web of Science ®Google Scholar
• Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357–2366.
   PubMed Web of Science ®Google Scholar
• Kim M, Park J, Kim DW, et al. Impact of IKZF1 deleteions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL. Bone Marrow Transplant. 2015;50:354–362.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. JCO. 2009;27:5202–5207.
   PubMed Web of Science ®Google Scholar
• Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128:504–507.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim DW, Cho BS, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2012;26:2367–2374.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122:1214–1221.
   PubMed Web of Science ®Google Scholar
• Lussana F, Intermesoli T, Gianni F, et al. Achieving Molecular Remission before allogeneic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact on relapse and long-term outcome. Biol Blood Marrow Transplant. 2016;22:1983–1987.
   PubMed Web of Science ®Google Scholar